Rob Dickerman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rob Dickerman has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ezek Mathew
Department of Microbiology and Immunology, The University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA
3 shared publications - Luke C. Cooksey
Department of Microbiology, Immunology and Genetics, University of North Texas Health, Fort Worth, TX 76107, USA
2 shared publications - Nirupama Sabnis
Department of Microbiology, Immunology and Genetics, University of North Texas Health, Fort Worth, TX 76107, USA
2 shared publications - Porunelloor Abraham Mathew
Department of Microbiology, Immunology and Genetics, University of North Texas Health, Fort Worth, TX 76107, USA
2 shared publications - Amalendu P. Ranjan
Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
1 shared publication - Bruce A. Bunnell
Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
1 shared publication
Latest Publications
- Open Access
- 30 April 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (5) , 487
Evolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers
Glioblastoma (GB) remains the most aggressive primary brain malignancy, with the Stupp regimen persisting as the standard of care for nearly two decades despite poor survival outcomes. This review was synthesized by extensively reviewing and analyzing the literature from PubMed, Scopus, and Web of Science to evaluate the emerging promising therapeutic and diagnostic strategies for combating GB. Results indicate significant progress in molecularly targeted therapies, biomimetic nanocarriers, and advanced radiotherapy. While immunotherapeutic approaches, such as checkpoint inhibitors and vaccines, show variable clinical success, the integration of bioinformatics and machine learning has significantly enhanced treatment response prediction. Furthermore, advances in radiomics and molecular imaging have improved the differentiation between true tumor progression and pseudoprogression, potentially reducing invasive diagnostic requirements. Additionally, other emerging and investigational adjuvant therapeutic approaches have shown promise. We conclude that, while multimodal strategies integrating molecular and computational approaches offer a path toward personalized GB management, significant barriers—namely tumor heterogeneity and the blood–brain barrier—persist. Future research must prioritize precision-based combinatorial models to successfully translate these preclinical advancements into improved clinical outcomes for patients.
- 30 April 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (5) , 487
Open AccessEvolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers
Glioblastoma (GB) remains the most aggressive primary brain malignancy, with the Stupp regimen persisting as the standard of care for nearly two decades despite poor survival outcomes. This review was synthesized by extensively reviewing and analyzing the literature from PubMed, Scopus, and Web of Science to evaluate the emerging promising therapeutic and diagnostic strategies for combating GB. Results indicate significant progress in molecularly targeted therapies, biomimetic nanocarriers, and advanced radiotherapy. While immunotherapeutic approaches, such as checkpoint inhibitors and vaccines, show variable clinical success, the integration of bioinformatics and machine learning has significantly enhanced treatment response prediction. Furthermore, advances in radiomics and molecular imaging have improved the differentiation between true tumor progression and pseudoprogression, potentially reducing invasive diagnostic requirements. Additionally, other emerging and investigational adjuvant therapeutic approaches have shown promise. We conclude that, while multimodal strategies integrating molecular and computational approaches offer a path toward personalized GB management, significant barriers—namely tumor heterogeneity and the blood–brain barrier—persist. Future research must prioritize precision-based combinatorial models to successfully translate these preclinical advancements into improved clinical outcomes for patients.
- Open Access
Cell-Surface PCNA Is Co-Expressed with Biomarkers of Stemness and Immunosuppression in Glioblastoma
Background/Objectives: Glioblastoma (GBM) is a lethal form of primary brain tumor. There has been minimal improvement in overall GBM survival in recent years. To increase survival in patients with GBM, it is important to study novel GBM molecular antigens to form the basis of better diagnostics, prognostic measures, and therapeutic advancements. Our goal is to find more robust GBM-specific antigenic biomarkers to eventually improve GBM outcomes. Here, we initiated an investigation into cell-surface PCNA (csPCNA), a potential GBM biomarker and antigenic target. Methods: We utilized flow cytometry, imaging flow cytometry, and cell-surface Western blot to identify the expression of csPCNA on GBM cell lines (LN-229, LN-18) and a primary patient-derived tumor specimen. We then employed flow cytometry to study the associative co-expression of csPCNA with other biomarkers of GBM stem cells (CD44, CD49f) and GBM immunosuppression (PD-L1, TGFβRII). Results: We elucidated that LN-229, LN-18, and the primary GBM patient cells express csPCNA. We found that csPCNA is co-expressed with CD44, CD49f, PD-L1, and TGFβRII on the primary patient-derived GBM specimen. Conclusions: Our findings that csPCNA is expressed in GBM and is co-expressed with stem cell and immunosuppressive biomarkers indicate that csPCNA may be a potentially useful clinical–pathological biomarker for GBM stemness and immunosuppression.
Open AccessCell-Surface PCNA Is Co-Expressed with Biomarkers of Stemness and Immunosuppression in Glioblastoma
Background/Objectives: Glioblastoma (GBM) is a lethal form of primary brain tumor. There has been minimal improvement in overall GBM survival in recent years. To increase survival in patients with GBM, it is important to study novel GBM molecular antigens to form the basis of better diagnostics, prognostic measures, and therapeutic advancements. Our goal is to find more robust GBM-specific antigenic biomarkers to eventually improve GBM outcomes. Here, we initiated an investigation into cell-surface PCNA (csPCNA), a potential GBM biomarker and antigenic target. Methods: We utilized flow cytometry, imaging flow cytometry, and cell-surface Western blot to identify the expression of csPCNA on GBM cell lines (LN-229, LN-18) and a primary patient-derived tumor specimen. We then employed flow cytometry to study the associative co-expression of csPCNA with other biomarkers of GBM stem cells (CD44, CD49f) and GBM immunosuppression (PD-L1, TGFβRII). Results: We elucidated that LN-229, LN-18, and the primary GBM patient cells express csPCNA. We found that csPCNA is co-expressed with CD44, CD49f, PD-L1, and TGFβRII on the primary patient-derived GBM specimen. Conclusions: Our findings that csPCNA is expressed in GBM and is co-expressed with stem cell and immunosuppressive biomarkers indicate that csPCNA may be a potentially useful clinical–pathological biomarker for GBM stemness and immunosuppression.
- Open Access
- 10 September 2025
- Published by MDPI AG in International Journal of Translational Medicine
- Vol. 5 (3) , 42
Evaluating Leucine, Isoleucine, and Valine Ratios in Mixed Cortical Cell Cultures Following Cortical Trauma: An In Vitro Assessment
Background/Objectives: Traumatic brain injury (TBI) remains the most common cause of morbidity and mortality in adolescents and adults. Although numerous animal and human studies have demonstrated the beneficial effects of branched-chain amino acids (BCAA) treatment on various models of brain injury, the optimal concentration and mechanism of action have not been elucidated. Methods: Based on our prior work, we hypothesized that a 2:1:1 ratio of BCAAs promotes neuronal regrowth and repair. Using in vitro mixed cortical cultures (composed of CNS cells, including neuronal and glial cells), we recapitulated the mechanical damage induced by TBI using the scratch assay model. We evaluated various concentrations of BCAA to promote the regrowth of CNS cells after mechanical damage. Results: A 2:1:1 ratio of leucine: isoleucine: valine was observed to yield superior regrowth rates at the 48 h time point across various concentrations when compared to a 1:1:1 ratio and even a 4:1:1 ratio. In addition, both 2:1:1 and 4:1:1 ratios offered multiple instances of accelerated regrowth, where less than 5% of the wound remained unhealed. Conclusions: The importance of leucine ratios in the context of BCAA treatment for TBI was demonstrated by the superior CNS cell regrowth offered by the 2:1:1 ratio.
- 10 September 2025
- Published by MDPI AG in International Journal of Translational Medicine
- Vol. 5 (3) , 42
Open AccessEvaluating Leucine, Isoleucine, and Valine Ratios in Mixed Cortical Cell Cultures Following Cortical Trauma: An In Vitro Assessment
Background/Objectives: Traumatic brain injury (TBI) remains the most common cause of morbidity and mortality in adolescents and adults. Although numerous animal and human studies have demonstrated the beneficial effects of branched-chain amino acids (BCAA) treatment on various models of brain injury, the optimal concentration and mechanism of action have not been elucidated. Methods: Based on our prior work, we hypothesized that a 2:1:1 ratio of BCAAs promotes neuronal regrowth and repair. Using in vitro mixed cortical cultures (composed of CNS cells, including neuronal and glial cells), we recapitulated the mechanical damage induced by TBI using the scratch assay model. We evaluated various concentrations of BCAA to promote the regrowth of CNS cells after mechanical damage. Results: A 2:1:1 ratio of leucine: isoleucine: valine was observed to yield superior regrowth rates at the 48 h time point across various concentrations when compared to a 1:1:1 ratio and even a 4:1:1 ratio. In addition, both 2:1:1 and 4:1:1 ratios offered multiple instances of accelerated regrowth, where less than 5% of the wound remained unhealed. Conclusions: The importance of leucine ratios in the context of BCAA treatment for TBI was demonstrated by the superior CNS cell regrowth offered by the 2:1:1 ratio.